TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02018510

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3 mg/kg, single dose IV administration of 3BNC117
Description: 3 mg/kg, single dose IV administration of 3BNC117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 mg/kg, single dose IV administration of 3BNC117
Description: 10 mg/kg, single dose IV administration of 3BNC117
Study: NCT03293511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal placebo
Description: 24 IU of of placebo nasal spray will be applied to each subject.
Study: NCT04211571

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Theranova 400 dialyzer
Description: Hemodialysis using Theranova 400 dialyzer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-flux dialyzer
Description: Hemodialysis using high-flux dialyzer
Study: NCT04541251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab + Nab-paclitaxel + Carboplatin
Description: The patients will receive three cycles (one cycle is defined as every 21 days +/- 3 days) of neoadjuvant therapy with camrelizumab 200 mg, nab-paclitaxel 260 mg/m2, and carboplatin AUC 5. This will then be followed by surgery.
Study: NCT01561027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNV1014802
Description: Administered as specified in treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in treatment arm
Study: NCT02018510

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 mg/kg, single dose IV administration of 3BNC117
Description: 10 mg/kg, single dose IV administration of 3BNC117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 mg/kg, single dose IV administration of 3BNC117
Description: 10 mg/kg, single dose IV administration of 3BNC117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 mg/kg, single dose IV administration of 3BNC117
Description: 30 mg/kg, single dose IV administration of 3BNC117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 mg/kg, single dose IV administration of 3BNC117
Description: 30 mg/kg, single dose IV administration of 3BNC117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 mg/kg, single dose IV administration of 3BNC117
Description: 30 mg/kg, single dose IV administration of 3BNC117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 mg/kg, single dose IV administration of 3BNC117
Description: 30 mg/kg, single dose IV administration of 3BNC117
Study: NCT00112398

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extended interventions by advanced level prehospital providers
Description: may include rapid sequence intubation (RSI) airway management, blood transfusions, surgical procedures, etc.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extended interventions by advanced level prehospital providers
Description: may include rapid sequence intubation (RSI) airway management, blood transfusions, surgical procedures, etc.
Study: NCT02318576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Computerized Cognitive Training: The online computer training program will be administered on the participants' home computer. The training program will consist of a total of 36 sessions (3 times/week for 12 weeks). Each session will last no more than 60 minutes and consist of five different cognitive exercises designed to improve cognitive processing speed, memory and executive function. All exercises will involve visual stimuli and a motor response (key or button press). Exercises will be adaptive to participants' individual ability and start with minimal difficulty.
Study: NCT01656174

Intervention type: DEVICE
Intervention: Procleix Dengue Virus Assay
Description: in vitro diagnostic assay
Study: NCT00786851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and Dexametasone
Description: Lenalidomide will be supplied as 5 mg and 25 mg capsules for oral administration.Dexamethasone (Soldesam 0.2%) will be supplied as 20 mg liquid for oral administration (1 bottle = 20 mg; daily dose = 2 bottles = 40 mg).
Study: NCT01475071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metvix and natural daylight PDT
Description: Methyl aminolevulinate, cream 160mg/g.One session at baseline and a second session administration at week 12 for lesions showing non-complete response and new lesions on target area.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metvix and conventional PDT
Description: Methyl aminolevulinate, cream, 160mg/g. One session at baseline and a second session administration at week 12 for lesions showing non-complete response and new lesions on target area.
Study: NCT00736177

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Embryo cryopreservation
Description: Subjects in the Test group will have their embryos cryopreserved for transfer in a subsequent cycle.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fresh embryo transfer
Description: Subjects in the Control group will receive fresh embryo transfer.
Study: NCT01116505

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gluten-free diet
Description: gluten-containing cereals removed from diet
Study: NCT03776344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality intervention - Oculus Rift HD
Description: During the VR experience patients will have the opportunity to choose from different VR environments (VR application - Nature Treks VR) and explore them using Oculus Rift Device.
Study: NCT01398085

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: I131 1.1 GBq
Description: Radio-iodine
Study: NCT03257228

Intervention type: GENETIC
Intervention: comparative semiquantitative immunohistochemistry

Intervention type: GENETIC
Intervention: comparative semiquantitative immunohistochemistry

Intervention type: GENETIC
Intervention: comparative semiquantitative immunohistochemistry
Study: NCT02374216

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Insertion of dental implants
Description: Evaluation of the failure rate of all dental implants, of any brand, inserted between September 1st 2014 to August 31st 2017
Study: NCT00550251

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupressure Wrist Bands (Sea-Bands)
Description: Elasticated wrist bands with active bead pressing on Pericardium 6 acupressure points bilaterally.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo wristbands
Description: Elasticated wrist bands without active bead.
Study: NCT02934529

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan 180 mg/m² iv, 30 - 90 min., day 1, q d15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 180 mg/m² iv, 30 - 90 min., day 1, q d15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 180 mg/m² iv, 30 - 90 min., day 1, q d15

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic Acid
Description: Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1, q d15
Study: NCT04487184

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Kinesiology taping
Description: Recently, kinesiology tape is a common intervention in clinic and sport. The tension caused by tape elasticity and attachment techniques affects the effects that kinesiology tape produces, such as pain relief, circulation increase, proprioception enhancement, and muscle contraction improvement.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kinesiology taping
Description: Recently, kinesiology tape is a common intervention in clinic and sport. The tension caused by tape elasticity and attachment techniques affects the effects that kinesiology tape produces, such as pain relief, circulation increase, proprioception enhancement, and muscle contraction improvement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiology taping
Description: Recently, kinesiology tape is a common intervention in clinic and sport. The tension caused by tape elasticity and attachment techniques affects the effects that kinesiology tape produces, such as pain relief, circulation increase, proprioception enhancement, and muscle contraction improvement.
Study: NCT02934529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1, q d15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1, q d15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1, q d15

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 5-FU 400 mg/m² bolus day 1, q d15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 400 mg/m² bolus day 1, q d15
Study: NCT02018510

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 mg/kg, single dose IV administration of 3BNC117
Description: 30 mg/kg, single dose IV administration of 3BNC117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 mg/kg, single dose IV administration of 3BNC117
Description: 30 mg/kg, single dose IV administration of 3BNC117
Study: NCT01107730

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin C
Description: VitC intravenously (2g/day \[500mgX4\] for 2 days prior to surgery, and postoperatively for 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-Carnitine
Description: L-Carnitine intravenously (2 gr/day \[1grX2\] for 2 days prior to surgery, and postoperatively for 4 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01375894

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: imitation assessment using the 5-dt data glove.
Description: measuring the speed of the hand during imitation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: imitation assessment using the 5-dt data glove.
Description: measuring the speed of the hand during imitation
Study: NCT03037229

Intervention type: DEVICE
Intervention: Smartphone ECG

Intervention type: DEVICE
Intervention: Smartphone ECG

Intervention type: DEVICE
Intervention: Standard 12-lead ECG
Study: NCT04487184

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiology taping
Description: Recently, kinesiology tape is a common intervention in clinic and sport. The tension caused by tape elasticity and attachment techniques affects the effects that kinesiology tape produces, such as pain relief, circulation increase, proprioception enhancement, and muscle contraction improvement.
Study: NCT02934529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 400 mg/m² bolus day 1, q d15
Study: NCT03037229

Intervention type: DEVICE
Intervention: Standard 12-lead ECG
Study: NCT00972946

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Administration of autologous Endorem-labelled mononuclear cells intravenously
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Endorem
Description: single dose, intravenous
Study: NCT02315612

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD22-CAR
Description: CD22-CAR cells will be infused on Day 0 after induction chemotherapy regimen.
Study: NCT02934529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 400 mg/m² bolus day 1, q d15

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 5-FU 2400 mg/m² iv over 46 h day 1-2, q d15
Study: NCT02934529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 2400 mg/m² iv over 46 h day 1-2, q d15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 2400 mg/m² iv over 46 h day 1-2, q d15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 2400 mg/m² iv over 46 h day 1-2, q d15

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) day 1 + 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) day 1 + 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) day 1 + 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 7.5 mg/kg BW iv over 30 to 90 minutes: day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1250 mg/m2 2 x day p.o. day 1-14, q d15

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: regorafenib
Description: 160 mg per day (day 1-21) (repeated on day 28)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan 125mg
Description: Irinotecan 125 mg/m² iv, 60 - 90 min. weekly (D1, D8, D15, D22)
Study: NCT03600441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abexinostat
Description: Abexinostat tosylate salt is formulated into an oral tablet formulation and is available in 20 mg strength.
Study: NCT02018510

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 mg/kg, two doses IV of 3BNC117
Description: 10 mg/kg, two IV administrations of 3BNC117 at weeks 0 and 12

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 mg/kg, two doses IV of 3BNC117
Description: 30 mg/kg, two IV administrations of 3BNC117 at weeks 0 and 12
Study: NCT01224353

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lipoic acid
Description: Tablet, 600mg, for oral use, 30 min before breakfast, once daily for 6 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet, placebo, 1-week single-blind placebo treatment then, 30 min before breakfast, once daily for 6 weeks
Study: NCT01125527

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib)
Description: a single dose was administered

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib)
Description: a single dose was administered
Study: NCT00944190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-management intervention
Description: Brief counseling technique, self-management,

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Educational information about pain, fatigue, depression, and cognitive difficulties in multiple sclerosis.
Study: NCT01715922

Intervention type: DRUG
Group type: OTHER
Intervention: Fluconazole
Description: Induction treatment for 2 weeks: Fluconazole (1600mg/j) Consolidation treatment for 8 weeks: fluconazole (800 mg/j)

Intervention type: DRUG
Group type: OTHER
Intervention: Flucytosine
Description: Flucytosine (100 mg/kg/j) for 2 weeks

Intervention type: PROCEDURE
Group type: OTHER
Intervention: lumbar punctures
Description: lumbar punctures to control intracranial pressure
Study: NCT02225015

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow-up Telephone Genetic Counselling
Description: Individualized theoretical genetic counselling among women with BRCA mutations to assess the impact it has on the uptake of cancer prevention strategies.
Study: NCT04323527

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine diphosphate
Description: 150mg chloroquine diphosphate tablets. Note: Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine diphosphate
Description: 150mg chloroquine diphosphate tablets. Note: Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine diphosphate
Description: 150mg chloroquine diphosphate tablets. Note: Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chloroquine diphosphate
Description: 150mg chloroquine diphosphate tablets. Note: Tablets used in the study were Chloroquine Diphosphate (produced by Farmanguinhos/Fiocruz), and the dosing stated in the clinicaltrials.gov refers to chloroquine base (in mg).
Study: NCT02017873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peroxide Carbamide 10% - Dental bleaching treatment
Description: During 3 hours in 3 weeks of bleaching in both groups in healthy patients and smokers patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peroxide Carbamide 10% - Dental bleaching treatment
Description: During 3 hours in 3 weeks of bleaching in both groups in healthy patients and smokers patients
Study: NCT01710722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caffeine and ephedrine
Description: Caffeine 200 mg tablets and ephedrine HCl 25 mg tablets three times a day with placebo leptin A-200 subcutaneously once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leptin A
Description: Leptin A-200 20 mg subcutaneously once daily and placebo tablets of caffeine and ephedrine three times a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: caffeine, ephedrine, and leptin A
Description: Caffeine 200 mg tablets and ephedrine HCl tablets 25 mg three times a day with leptin A-200 20 mg subcutaneously once daily.
Study: NCT04418219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: alkylating agent used in the treatment of several forms of cancer including leukemias, lymphomas and breast cancer.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic GM-CSF-secreting Breast Cancer Vaccine SV-BR-1-GM
Description: Breast Cancer Vaccine SV-BR-1-GM, Bria-IMT, GM-CSF Gene-transfected Breast Cancer Vaccine SV-BR-1-GM, SV-BR-1 Breast Cancer Cell Line Vaccine, SV-BR-1-GM, SV-BR-1-GM Vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 1374853-91-4, Immunoglobulin G4, Anti-(Human Programmed Cell Death 1); Humanized Mouse Monoclonal (228-L-proline(H10-S\>P))gamma 4 Heavy Chain (134-218'')-disulfide with Humanized Mouse Monoclonal Kappa Light Chain Dimer (226-226'''':229-229'''')-bisdisulfide, Keytruda, Lambrolizumab, MK-3475, PEMBROLIZUMAB, SCH 900475

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alpha 2b-like Protein
Description: Novaferon, Recombinant IFN Alfa-2b-like Protein

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Assessment
Description: Ancillary studies
Study: NCT00529763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 70 mg BID (AD CML) or 100 mg QD (Chronic CML), once or twice daily dependent on disease stage, until subjects meet discontinuation (DC) criteria for study
Study: NCT03293563

Intervention type: PROCEDURE
Intervention: Radical nephrectomy versus partial nephrectomy (according surgeon judgement)
Study: NCT01704560

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coversheet to Informed Consent
Description: The intervention is a one page cover sheet to be affixed to the front of the standard permission form for the trial for which permission is being sought (attached to application). The form will identify the study as research and contain sections that include investigator contact information, the purpose of the study, a brief description of the study procedures, the alternatives, the voluntary nature, the risks, the potential benefits, a discussion of privacy and confidentiality, the costs and the payments. Each topic will also contain a reference to the page in the consent containing the full description of the topic. The form is designed to have a reading level no higher than 6th to 8th grade. Parents will also receive the full permission form, and all required signatures will still be collected on the permission form.
Study: NCT01192477

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Ozone
Description: All subjects will have a 3-hour exposure to clean air, a 3-hour exposure to clean air with lower ozone (0.1 ppm), and a 3-hour exposure to clean air with higher ozone (0.2 ppm). Exposures will take place at least 3 weeks apart. Order of exposure will be randomized for each subject.
Study: NCT02934529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab wkly
Description: Cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) weekly (D1, D8, D15, D22, D29, D36)
Study: NCT03083860

Intervention type: DEVICE
Group type: OTHER
Intervention: BEI
Description: BrainMARC Ltd. has demonstrated in recent years the ability to extract effective attention markers from averaged ERP waves sampled with a single EEG channel (two electrodes). In addition, BrainMARC has developed a template matching method to extract the attention-related markers at the single-trial level. An index (termed Brain Engagement Index - BEI) can then be generated from a 1-minute, single-channel sample.

Intervention type: DEVICE
Group type: OTHER
Intervention: BEI
Description: BrainMARC Ltd. has demonstrated in recent years the ability to extract effective attention markers from averaged ERP waves sampled with a single EEG channel (two electrodes). In addition, BrainMARC has developed a template matching method to extract the attention-related markers at the single-trial level. An index (termed Brain Engagement Index - BEI) can then be generated from a 1-minute, single-channel sample.
Study: NCT01192477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone
Description: All subjects will have a 3-hour exposure to clean air, a 3-hour exposure to clean air with lower ozone (0.1 ppm), and a 3-hour exposure to clean air with higher ozone (0.2 ppm). Exposures will take place at least 3 weeks apart. Order of exposure will be randomized for each subject.
Study: NCT02808091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIFOX-Bortezomib
Description: GIFOX-Bortezomib will be given every 21 days for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIFOX-Bortezomib
Description: GIFOX-Bortezomib will be given every 21 days for a total of 6 cycles.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: a minimum of 50 Gy of IMRT to tumor bed and neck (5 weeks)